TICKERNOMICS Sign up
Last Update: 2024-12-27 15:28:06
Aerovate Therapeutics Inc. ( AVTE ) https://aerovatetx.com
2.63USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-88.84%
AVTE
SPY
32.66%
-73.83%
AVTE
SPY
108.59%
AVTE
0.00%
SPY
302.52%
AVTE
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
75.04
-13.15
0.13
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.89
551.80
0.93
-133.77
0.00
0.15
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-18101.47
-20.59
-15645.40
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-504.00
-72.15
0.00
Other Earnings and Cash Flow Stats:
Aerovate Therapeutics Inc. ( AVTE ) Net Income TTM ($MM) is -84.61
Aerovate Therapeutics Inc. ( AVTE ) Operating Income TTM ($MM) is -90.26
Aerovate Therapeutics Inc. ( AVTE ) Owners' Earnings Annual ($MM) is 0.00
Aerovate Therapeutics Inc. ( AVTE ) Current Price to Owners' Earnings ratio is 0.00
Aerovate Therapeutics Inc. ( AVTE ) EBITDA TTM ($MM) is -89.96
Aerovate Therapeutics Inc. ( AVTE ) EBITDA Margin is -15645.40%
Capital Allocation:
Aerovate Therapeutics Inc. ( AVTE ) has paid 0.00 dividends per share and bought back -1.222785 million shares in the past 12 months
Aerovate Therapeutics Inc. ( AVTE ) has reduced its debt by 0.269 million USD in the last 12 months
Capital Structure:
Aerovate Therapeutics Inc. ( AVTE ) Interest-bearing Debt ($MM) as of last quarter is 0
Aerovate Therapeutics Inc. ( AVTE ) Annual Working Capital Investments ($MM) are 0
Aerovate Therapeutics Inc. ( AVTE ) Book Value ($MM) as of last quarter is 80
Aerovate Therapeutics Inc. ( AVTE ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Aerovate Therapeutics Inc. ( AVTE ) has 31 million in cash on hand as of last quarter
Aerovate Therapeutics Inc. ( AVTE ) has 10 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Aerovate Therapeutics Inc. ( AVTE ) has 28 common shares outstanding as of last quarter
Aerovate Therapeutics Inc. ( AVTE ) has 0 million USD of preferred stock value
Academic Scores:
Aerovate Therapeutics Inc. ( AVTE ) Altman Z-Score is -1.24 as of last quarter
Aerovate Therapeutics Inc. ( AVTE ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Aerovate Therapeutics Inc. ( AVTE ) largest shareholder is owning shares at 0.00 ($MM) value
Kolchinsky Peter(an insider) Bought 928110 shares of Aerovate Therapeutics Inc. ( AVTE ) for the amount of $1549943.70 on 2024-06-17
0.03% of Aerovate Therapeutics Inc. ( AVTE ) is held by insiders, and 102.17% is held by institutions
Aerovate Therapeutics Inc. ( AVTE ) went public on 2021-06-30
Other Aerovate Therapeutics Inc. ( AVTE ) financial metrics:
FCF:-75.08
Unlevered Free Cash Flow:0.00
EPS:-2.25
Operating Margin:-18101.47
Gross Profit Margin:-20.59
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-80.69
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Aerovate Therapeutics Inc. ( AVTE ) :
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.